For debate new therapeutic products and difficult decisions. The case of recombinant factor viii in the management of haemophilia a

Journal of Public Health (United Kingdom)

Volumn 20, Issue 2, 1998, Pages 137-138

  Green, Colin ^a   Akehurst, Ron ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

haemophilia; purchaser guidance

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ARTICLE; DRUG COST; HEMOPHILIA A; HUMAN; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURCHASING; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; FACTOR VIII; GREAT BRITAIN; HEALTH EXPENDITURES; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 0032087638     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/oxfordjournals.pubmed.a024732     Document Type: Article

References (7)

1. United Kingdom Haemophilia Centre Directors Organization Executive Committee. Guidelines on therapeutic products to treat haemophilia and other hereditary disorders. Haemophilia 1997; 3: 31-37.
2. Ludlam CA, Hay CRM, Dolan G. Treatment for haemophilia by postcode. Br Med J 1997; 314: 749.
3. Anthony D, Milne R. On-demand recombinant factor VIII for people with haemophilia A. Development and Evaluation Committee Report 71. Southampton: Wessex Institute for Health Research and Development, 1997.
4. Chishohn DK, ed. Recombinant factor VIII-report of a multi-professional group. Manchester: NHSE, North West Regional Office, 1997.
5. NHS Executive, Northern and Yorkshire, Regional Drug and Therapeutics Centre. Use of recombinant factor VIII in the management of haemophilia A. Durham: NHS Executive, Northern and Yorkshire, 1997.
6. Green C, Akehurst L. Recombinant factor VIII versus plasma derived factor VIII in the management of haemophilia A: an examination of the costs and consequences. Guidance Note for Purchasers 97/04. Sheffield: Trent Institute for Health Services Research; Universities of Leicester, Nottingham and Sheffield, 1997.
7. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality before and after HTV infection in the complete UK population of haemophiliacs. Nature 1995; 377: 79-82.